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ABSTRACT
Clinical trials for rare neuromuscular diseases imply, among other
investments, a high emotional burden for the whole disease
community. Translation of data from preclinical studies to justify any
clinical trial must be carefully pondered in order to minimize the risk of
clinical trial withdrawal or failure. A rigorous distinction between proof-
of-concept and preclinical efficacy studies using animal models is key
to support the rationale of a clinical trial involving patients. This
Review evaluates the experience accumulated by the TREAT-NMD
Advisory Committee for Therapeutics, which provides detailed
constructive feedback on clinical proposals for neuromuscular
diseases submitted by researchers in both academia and industry,
and emphasizes that a timely critical review of preclinical efficacy data
from animal models, including biomarkers for specific diseases,
combined with adherence to existing guidelines and standard
protocols, can significantly help to de-risk clinical programs and
prevent disappointments and costly engagement.
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Introduction
Animal models of human genetic diseases are useful for several
reasons. Firstly, they allow the study of mechanisms of a specific
disease at different stages and in association with development,
growth and aging, by sampling different types of tissues and fluids,
and by assessing the animals functionally in a manner that is
relevant to the disease. This facilitates a better understanding of the
disease and aids in identifying potential new therapeutic targets.
Secondly, animal models enable the testing of experimental
therapies. For neuromuscular diseases, much of the knowledge we
have today about how muscle conditions evolve, and which
pathways are affected, derives from studies in mice and other
model organisms. This vital in vivo knowledge helps to identify
druggable targets and to design or test specific therapeutic
modalities, as well as to detect diagnostic or therapeutic
biomarkers. Animal models also allow the comparison of
pathological phenotypes with the human disease, and focused
studies may help to gain insight into the underlying reasons for
differences at varying levels of complexity. This can also have an
important impact on the translational effort, allowing the
identification of protective pathways in animals that could be
enhanced in humans.
Animal models are widely used to preclinically test novel
therapeutics, including small molecules, biologics, gene modifiers
and cell therapies. However, translation of a potential therapy with
proven preclinical efficacy to the human setting is much more
challenging. In part, this is owing to differences in the nature of the
disease pathology in humans. Some inherited neuromuscular
diseases have the advantage of a clear genotype-phenotype
correlation allowing more direct approaches via the modulation
of the main target of the pathology (e.g. certain muscle
channelopathies). Others, although monogenic, are more complex,
as a mutation may not be fully penetrant, or the monogenic defect
can trigger a complex cascade of pathological events and the mutant
allele may exhibit variations that depend on the broader genetic
environment. Also, certain mouse genetic backgrounds may include
genetic modifiers that influence the overall manifestation of
pathology and make it harder to translate drug efficacy to
humans. However, even these so-called ‘imperfect’ models offer a
unique opportunity to gather essential information on the
pathogenesis and on the targeting of specific pathways for therapy
development, provided one is aware of the limitations of the model
and takes them into consideration when interpreting the data and
translating it to the clinical setting.
One important, and often underestimated, aspect to consider
when evaluating clinical translatability is the rigor and robustness of
the preclinical studies and their reproducibility, which allows
comparison and confirmation of results from different labs. In many
instances, a candidate therapy proceeds to a clinical setting,
especially for a limited patient population, based on tissue culture
studies or an ‘extraordinary’ proof-of-concept finding in an animal
model without wider preclinical validation, paving the way for a
highly risky and most likely suboptimal process of translation to the
clinic. In fact, this process frequently fails owing to an
underestimation of crucial variables. Such clinical failure is often
explained by an intrinsic limitation of the animal model in fully
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recapitulating the human disease. But in reality, it may be due to a
lack of strong preclinical data for the proposed therapy, including
optimal dosing regime and route. Overall, this triggers a loss of faith
in the usefulness of model animals for the development of
treatments. Although the quick translation of therapeutic
compounds into clinical trials, based on premature preclinical
results, is commonly used to move forward in the drug development
process (Kimmelman et al., 2014), it in fact hampers it by increasing
the chance of failure, where it is unclear whether the clinical trial
failed because the test compound was ineffective or because the trial
rationale or design were suboptimal (Scott et al., 2008). In the
context of rare diseases, this is aggravated by the participation of the
already very small number of patients in trials that have limited
potential to succeed and/or provide a clear outcome.
Background
Launched in 2007, the EU-funded network of excellence for genetic
neuromuscular diseases, Translational Research in Europe for the
Assessment and Treatment of Neuromuscular Disorders (TREAT-
NMD; FP6 contract number EC 036825), aimed at addressing the
clinical translation problem by harmonizing best practices and tools
in Europe to accelerate the development of effective treatments for
neuromuscular diseases, with an initial focus on Duchenne
muscular dystrophy (DMD) and spinal muscular atrophy (SMA).
The network quickly expanded outside European boundaries and
embraced other neuromuscular diseases, for which standards of
care, international registries and biobanks were developed and
launched. In the preclinical research space, it was clear that the
fragmentation of research approaches and the lack of guidelines to
define the level of rigor required to promote a preclinical study for
translation into humans were key aspects to address. TREAT-NMD
strongly promoted an ambitious international effort to develop
Standard Operating Procedures (SOPs) under the consensus of key
scientists for the assessment of the most important animal readouts
in a more reproducible way (Grounds et al., 2008; Nagaraju and
Willmann, 2009; Willmann et al., 2011; see also https://treat-nmd.
org/research-overview/preclinical-research/). In place since 2009,
the use of SOPs is increasingly required by the National Institutes of
Health and other funding bodies for grant assessment or also in
preparation of scientific advicemeetings on investigational new drugs.
Accordingly, the use of SOPs ismentioned in several publications (for
example George Carlson et al., 2011; Israeli et al., 2019; Mantuano
et al., 2018; Mele et al., 2019; Tam et al., 2015; Zschüntzsch et al.,
2016). The TREAT-NMD website has recorded more than 11,000
SOP downloads over 7 years. The network progressively developed
additional guidelines and recommendations, and held workshops to
improve the quality and robustness of preclinical studies, to
increase transparency in reporting and as independent validation
(Willmann et al., 2015, 2012). This effort with multiple stakeholders
is highly dynamic, continuously involving novel animal models and
technical advancement in experimental strategies (see for example
Gordish-Dressman et al., 2018; Willmann et al., 2018).
TREAT-NMD also strived to consolidate a ‘modus operandi’ that
could be widely accepted by the community for the sake of the
community itself: all interested stakeholders, including editors and
funding agencies, should be aware that the quality of preclinical data
for translational research needs to be predominantly robust,
reproducible and less focused on novel and sensational results
(Willmann et al., 2018). This process can be in part ensured with a
clear distinction between proof-of-concept preclinical studies, often
aimed at target validation with an interesting candidate molecule,
and clinically-oriented ones that are aimed at the translational effort
and that are built with the rigor that resembles clinical trials and/or
the toxicology data package required for drug approval (Grounds
et al., 2008; Willmann et al., 2015).
The TREAT-NMD Advisory Committee for Therapeutics
The TREAT-NMD Advisory Committee for Therapeutics (TACT,
launched in 2009) is a unique multi-disciplinary international group
of well recognized neuromuscular healthcare, academic and
industry drug development experts, as well as representatives of
patient organizations and experts in regulatory affairs. The aim of
TACT is to review therapy development programs submitted by
academia or industry and provide guidance and advice on the
different aspects of translational research. An overall view of
TACT’s structure and outputs after 5 and 10 years of activity has
been described in Heslop et al. (2015) and Wagner et al. (2019).
This Review focuses on the challenges of the preclinical phase of
drug development and aims to recommend measures to avoid the
waste of resources, making use of the experience collected over the
10 years of the TACT program.
A schematic of the typical TACT proposal workflow is
available on https://treat-nmd.org/tact-treat-nmd-advisory-committee-
for-therapeutics/tact-application-process/. Whatever the stage of the
program application submitted to TACT, the committee performs a
careful evaluation of preclinical data in order to provide guidance or
to uncover possible bias that could negatively affect the clinical trial
design, or on the proper identification of therapeutic biomarkers and
clinically meaningful endpoints. The robustness of the available data
is checked according to the guidelines developed by TREAT-NMD
and the SOPs available or, alternatively, according to the wider
scientific community’s best knowledge available on the animal
model or preclinical setting proposed in the program application.
Based on the experience accumulated by TACT, we analyze here
the compliance with guidelines and standards in the neuromuscular
research community, evaluate the effort to improve translational
efficacy for the benefit of patients, and estimate the impact that
TACT has had on the development and success of clinical trials for
neuromuscular diseases.
Results
TACT advice on the preclinical assessment of therapeutic programs
from 2010-2019
In 10 years of activity up to April 2019, TACT has provided
guidance to 56 development programs. At the time of writing this
Table 1. The most common pieces of TACT advice, and their
frequencies in %, given to strengthen preclinical evidence of efficacy
of 56 programs submitted between 2010 and 2019
TACT advice to applicants
Frequency
(%)
Dose or administration route not clinically relevant or not
appropriate
36
Readouts or tissue choice not relevant for the question 34
Preclinical data do not support or are unrelated to the claimed
efficacy
30
External (independent) validation requested 29
Concerns regarding control groups, randomization or blinding 29
Encouragement to use available SOPs 27
Additional model requested; available animal model not tested 27
Additional data requested 21
Concerns on the choice of animal age, gender or study length 20
Statistical design not sufficiently powered or lacking key details 14
Inappropriate statistical analysis 7
Insufficient reporting of experimental conditions 5
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Review, 59%were in the preclinical phase, 32%were in clinical trial
phase I and 9% were in phase II.
During the evaluations of the preclinical programs submitted to
TACT, some common themes emerged from the review reports
(Table 1). Inappropriate doses/administration route, inappropriate
readouts or inappropriate tissue choice for a given readout were the
most frequent issues identified by TACT. Randomization, blinding
and appropriate controls were missing in 30% of the programs
submitted to TACT (Table 1). The availability and the proper use of
biomarkers in the preclinical phase depends on the disease and on
the expected mechanism of action of the drug. For the general
purpose of this Review, we therefore decided not to include this
issue in the overall evaluation of the preclinical programs.
In general, only few programs had no issues on the preclinical
assessment (9%). Most programs were given one to three of the
advices listed in Table 1. Almost 30% of the programs submitted to
TACT at preclinical stage or at phase I clinical trial stage, and 17%
of the programs submitted at phase II clinical trial stage, were given
four to six pieces of advice to strengthen the preclinical assessment
(Fig. 1).
Applications originated from academia (32%), from small
companies with 50 employees or fewer (45%), from medium-
sized companies with 51-250 employees (7%) and from big pharma
companies with more than 250 employees (16%) (Wagner et al.,
2019). In relation to the type of applicant, most programs that did
not receive any additional recommendation for their preclinical
assessment were submitted by medium-size enterprises and
big pharma. However, all categories of applicants submitted
programs that did receive recommendations on their preclinical
development (Fig. 2).
Development of clinical trials after TACT advice
We reviewed the number of TACT programs that progressed to
clinical trials over the years. Fewer programs that were reviewed by
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Fig. 1. Recommendations on preclinical
data given to TACT applicants. The
x-axis shows the number of items of TACT
advice (see Table 1) given to applicants in
relation to the development phase of the
research program at the application date.
For example, 61% of programs submitted
at the preclinical phase were given
between one and three items of TACT
advice.
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Fig. 2. Distribution of TACT advice according to applicant type. The x-axis shows the percentage of programs for which TACT identified pre-clinical issues.
For example, in 61% of the programs coming from academia, TACT provided one to three items of advice in the preclinical assessments.
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TACT at a preclinical stage progressed to a subsequent clinical
trial (30%) than programs reviewed at a later planning phase
(60%, Fig. 3A).
Considering that the initiation of a clinical trial is a lengthy
process, we redrew this figure considering only programs submitted
until spring 2017 and observed a slight increase in these
percentages: 45% of programs submitted at preclinical stage and
69-75% of programs submitted at a later stage result in an ongoing
or completed trial in 2019 (Fig. 3B).
However, the rates of progress to clinical trials (ongoing and
completed trials) is similar for all categories of applicant, with a
clearly lower success rate observed for medium enterprises (Fig. 4).
This could be explained by the fact that of the five medium-sized
enterprises that applied for a TACT review up to 2017, two did not
have a focus on neuromuscular diseases at the date of application.
Data in Fig. 4 suggest that the higher number of programs submitted
to TACT at a preclinical stage and not yet progressed to clinical
trials, as shown in Fig. 3A, probably reflects the value of early-stage
feedback, which presents the opportunity to revise the trial design
and planning. TACT advice may have indicated the importance of
additional preparatory work asking the right questions early in
program development. An objective critical assessment in the early
stage of planning of a clinical program is essential to avoid the waste
of resources that can result from premature initiation of a suboptimal
clinical trial.
Indeed, this can be partly confirmed by considering the
percentage of trials registered on the clinicaltrials.gov portal that
needed to be withdrawn. To simplify, we looked at DMD trials only,
based on the fact that the great majority of TACT-reviewed
programs developed interventions for DMD (Heslop et al., 2015).
We compared the number of trials for DMD that underwent a TACT
review but were never started with the global number of trials for
DMD that were registered on clinicaltrials.gov in the same time
period but were stopped before conclusion. Fig. 5A shows that, in
this subset, almost half of the trials were never started after their
proponents received TACT advice. In the same time period, 30% of
interventional trials in DMD registered on clinicaltrials.gov had to
be withdrawn or terminated ahead of time (Fig. 5B). This supports
the observation that a timely critical review of the preclinical data
may prevent the translation of a weak program into a patient trial,
and may result in the reduction of unsuccessful clinical trials.
Indeed, only one of the 37 TACT-reviewed programs on DMD that
eventually progressed to a clinical trial was discontinued, whereas
36 are still ongoing or are completed.
Discussion
In the field of rare diseases, researchers need to plan clinical trials
particularly well. This is because, even in the best scenarios, the
numbers of eligible patients are limited. It is further complicated by
the fact that most rare diseases have no therapies available, and
therefore often lack post-marketing, real-world data. Owing to the
unmet medical need, unsuccessful or terminated clinical trials are
generally very damaging for the communities involved. Researchers
increasingly recognize that most preclinical experiments do not
represent a true preclinical efficacy study. In the past decades,
discussions on the value of mouse models in predicting a therapy’s
efficacy for humans concluded that preclinical efficacy studies for
therapies that aim at transition to clinical trials should be conducted
with the same rigor as the clinical trials themselves (Conwit et al.,
2011; Knopp et al., 2015). To help achieve high-quality preclinical
studies, primary and secondary outcomes should be defined in
advance and assessed according to standardized protocols, adequate
control groups need to be chosen, and power analysis should be used
to determine sample size; randomization and blinding need to be
implemented, and a careful statistical analysis should be applied.
The choice of readouts and biomarkers needs to be tailored to the
drug tested and to the expected efficacy, both on the molecular level
and for functional, clinically relevant aspects. Notably, as in human
trials, preclinical studies can only be properly planned when the
natural history of the model system is known (see for example
Gordish-Dressman et al., 2018; van Putten et al., 2019; Verhaart
et al., 2019), as this will also guide researchers in determining
when to start the intervention and when and how to assess its
therapeutic effects.
However, there are no predetermined rules, for example by
regulatory authorities, to define the conduct of clinically-oriented
preclinical studies for rare diseases, and the enthusiasm about new
findings sometimes leads to haste and unrealistic expectations of
translation to humans. This frequently means a lack of rigorous
controls, independent validation and proper sample sizes. Aware of
this problem, TACT carefully reviews all the preclinical data in the
submitted programs. Where data are missing or unclear, the
committee explicitly recommends clarification or additional items.
Clinical trial status in 2019
A  Phase of application, 2010-2019
B  Phase of application, 2010-2017
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Fig. 3. Clinical trial status in 2019 related to stage of development at the
TACT submission date. (A) Clinical trial status in 2019 related to stage of
development at the TACT submission date 2010-2019. Programs that were
submitted at their preclinical phase have not yet resulted in a clinical trial in 70%
of the cases (blue bar), whereas 30% (orange and gray bars) resulted in trials
that are still ongoing or completed. (B) Clinical trial status in 2019 related to
stage of development at the TACT submission date 2010-2017. Considering
programs submitted until spring 2017, the rate of continuing into clinical trials
slightly increases.
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A recent analysis of the adequacy of the mouse versus dogmodel for
DMD, according to the question posed, confirms that researchers
need to make a careful choice before assessing the efficacy of
treatments in animals (Ferreira et al., 2019).
Despite the broad discussion on the need for rigor in preclinical
studies and the publication of recommendations, guidelines and
consensus papers on this topic (Bøtker et al., 2018; Henderson et al.,
2013; Smith and Houghton, 2013; Tuzun et al., 2015), basic issues
are still present in much of the preclinical efficacy data submitted to
TACT. These include a lack of randomization, blinding and
adequate controls (Table 1). In the 10 years of TACT experience,
it has become clear how often preclinical data, which are used as the
rationale to start a human trial, lack one or more of the basic
recommendations. The percentage of programs submitted to TACT
that attempted the transition to clinical trials based on poor
preclinical efficacy studies predicts the risk of unsuccessful trials
(Fig. 1). Both academia and industry planning clinical trials
submitted programs containing preclinical studies that were missing
up to eight of the 12 basic aspects regarded as key for meaningful
preclinical efficacy studies, with the highest numbers occurring in
programs submitted by academia and small- to medium-sized
enterprises (Fig. 2).
It is essential to underscore again, at this stage, that exploratory
and proof-of-concept studies are different from the subsequent
preclinical (translationally-oriented) efficacy ones. The former raise
treatment hypotheses or use drugs to validate a pathology-related
pathway and can generate much excitement. The latter typically
follow proof-of-concept work and are carefully designed with the
aim to test and prove the efficacy for a possible future clinical
application on humans. The existing guidelines and their required
rigor are necessary for the latter category of preclinical studies.
Specific SOPs for the assessment of readouts in distinct animal
models now provide researchers with a platform of standardized
methods for proper use of animal models, in order to obtain robust
and reproducible results. According to this point, independent
validation of a preclinically tested compound is another key point to
consider (Capogrosso et al., 2018).
We observed that a critical assessment of the preclinical data
meant to support a future clinical trial in rare diseases (as assisted by
TACT) may contribute to more time invested in robust conclusive
preclinical studies to strengthen efficacy data and reduce the risk of
unsuccessful clinical trials (Figs 3–5). At the same time, this also
avoids including patients in trials that have a low probability of
success, and the associated exclusion of the same limited pool of
patients from more promising trials.
Conclusions
In spite of the 15 years of efforts in educating and raising awareness
within the academic and industry communities about the
importance of rigor in clinical translation-oriented animal studies
for rare diseases, this ‘real world’ analysis through TACT reviews
underlines that the quality of preclinical data supporting the
‘efficacy’ of a drug or therapy is too often still limited or
scattered. Although it is accepted that animal studies are
necessary to provide data on the in vivo mechanism, target
engagement, efficacy, dosage and biomarker development, the
need for more preclinical studies to enhance data quality is
questioned based on the often-quoted statement that animal
models poorly represent human disease. Actually, an animal
model, when properly used, can be highly informative and
prevent the huge waste of resources, time, and imposition on
patient populations of poorly justified or poorly designed clinical
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Fig. 4. Clinical trial status in 2019 related
to applicant type, 2010-2017. Programs
submitted before spring 2017 developed
into a clinical trial in ∼50% of the cases
(orange and gray bars).
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Fig. 5. Status of clinical trials in 2019 for DMD programs. (A) Status of
clinical trial in 2019 for DMD programs submitted to TACT 2010-2017.
(B) Status of all DMD clinical trials in 2019 registered on clinicaltrials.gov
2010-2017. Almost 30% of the DMD trials needed to be stopped ahead of
completion, indicating a high rate of failure that could probably be reduced by a
careful evaluation of the preclinical evidence and its readiness for translation
to the clinical setting.
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trials. Validation of target engagement in proof-of-concept studies
and assessment of efficacy in properly designed clinically-oriented
preclinical studies can also support toxicology studies, and help
dose finding and pharmacokinetic/pharmacodynamic assessments
(Heier et al., 2013; Meyer et al., 2015).
Although the requirements for toxicology assessment of new
drugs are clearly defined, no regulation is available for the
preclinical pharmacology data used to support a human trial
(Langhof et al., 2018). Similarly, the absence of requirements for
reporting standards in scientific publications has led to efforts in
compiling ARRIVE guidelines (Kilkenny et al., 2010), but their
implementation by journals is still very poor (Hair et al., 2019).
Therefore, the scientific, clinical and industry communities, in
parallel with regulators, need to be actively aware of the risk of using
a poor data set from animal models for premature translation to a
human trial.
Based on the observations discussed in this Review, TACT
suggests referring to the TREAT-NMD guidelines and SOPs as a
checklist to plan clinically-oriented preclinical studies and improve
the strength of the scientific rationale for a clinical trial. Although in
2015, 72% of all programs submitted to TACT developed
interventions for DMD (Heslop et al., 2015), in 2019 this was
reduced to 66%, and TACT registered an increased broader
development of treatments for other diseases (Wagner et al.,
2019). Therefore, a standard evaluation of existing animal models
for less common neuromuscular diseases and the generation of
specific SOPs and guidelines would help the wider research
community conducting reproducible and robust preclinical efficacy
studies.
At the moment, there are not enough ongoing trials that originally
applied for TACT advice to draw conclusions about the impact of
the advisory feedback on successful development of a therapeutic.
However, the collected experience suggests that TACT may better
help applicants whose translational projects are in the early phases
of development, provided that a candidate drug at good
manufacturing practice quality and ready for human use,
including its main toxicology data set, is available. Concluding
from the remarks of many TACT applicants (see Box 1, Feedback
from past TACT applicants), having multidisciplinary drug
development experts at the table is considered valuable and
important to independently review the scientific rationale for a
drug. Definitively, an appropriate robust preclinical data package
has a chance to de-risk, prevent disappointments, reduce costs and
avoid unnecessary and highly taxing engagement of a limited
patient population.
This article is part of a special collection ‘A Guide to Using Neuromuscular Disease
Models for Basic and Preclinical Studies’, which was launched in a dedicated issue
guest edited by Annemieke Aartsma-Rus, Maaike van Putten and James Dowling.
See related articles in this collection at http://dmm.biologists.org/collection/
neuromuscular.
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